How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

613 results for

Pediatric Auditory Screening

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation

and function, in adults with multiple myeloma who are treated with high-dose chemotherapy followed by ASCT. Condition or disease Intervention/treatment Phase Multiple Myeloma Diagnostic Test: Structural Image Diagnostic Test: Functional Image Behavioral: Digit Span subtest Behavioral: Brief Test of Attention Behavioral: Trail Making Test (Parts A & B) Behavioral: Auditory Consonant Trigrams Test Behavioral: Controlled Oral Word Association Test Behavioral: Hopkins Verbal Learning Test-Revised Behavioral (...) ) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT. Other Name: rsfMRI Behavioral: Digit Span subtest Evaluates auditory attention and working memory Other Name: WAIS-IV Behavioral: Brief Test of Attention Assesses selective auditory attention Other Name: BTA Behavioral: Trail Making Test (Parts A & B) Assesses visual scanning, graphomotor speed, and setshifting Behavioral: Auditory Consonant Trigrams Test Assesses attention and susceptibility to interference Behavioral

2018 Clinical Trials

142. HIRREM for Stage 1 Primary Hypertension

Intervention/treatment Active Comparator: HIRREM High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time. Device: HIRREM Technology Other Names: High-resolution, relational, resonance-based, electroencephalic mirroring Brainwave Optimization Other (...) ] The CES-D is a 20-item survey assessing affective depressive symptomatology to screen for risk of depression. Scores range from 0-60, with a score of 16 commonly used as a clinically relevant cut-off. Higher scores indicate the presence of more symptomatology. Change in Generalized Anxiety Disorder-7 (GAD-7) [ Time Frame: Baseline, 1-14 days post final session, 4-6 weeks post final session, 12-14 weeks post final session ] The GAD-7 is a seven item screening tool for anxiety that is widely used

2018 Clinical Trials

143. Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials

with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device (...) flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60

2018 Clinical Trials

144. Baby's First Years

and Young, 1993). Child Socioemotional Development [ Time Frame: Age 12 months ] Social and Emotional Behaviors Measured by Brief Infant-Toddler Social and Emotional Assessment (BITSEA) Reference: Briggs-Gowan, M. J., Carter, A. S., Irwin, J. R., Wachtel, K., & Cicchetti, D. V. (2004). The Brief Infant-Toddler Social and Emotional Assessment: screening for social-emotional problems and delays in competence. Journal of pediatric psychology, 29(2), 143-155. Child Socioemotional Development [ Time Frame (...) : Age 24 months ] Social and Emotional Behaviors Measured by Brief Infant-Toddler Social and Emotional Assessment (BITSEA) Reference: Briggs-Gowan, M. J., Carter, A. S., Irwin, J. R., Wachtel, K., & Cicchetti, D. V. (2004). The Brief Infant-Toddler Social and Emotional Assessment: screening for social-emotional problems and delays in competence. Journal of pediatric psychology, 29(2), 143-155. Child Socioemotional Development [ Time Frame: Age 36 months ] Social and Emotional Behaviors Measured

2018 Clinical Trials

145. Evidence Amyloid Scan EEG Study

EEG P300/P50 system, along with the structured clinical interviews and assessments for baseline screening or mild cognitive impairment which are standard of care. Condition or disease Intervention/treatment Alzheimer Disease Dementia Frontal Mild Cognitive Impairment Device: EEG scan Study Design Go to Layout table for study information Study Type : Observational [Patient Registry] Estimated Enrollment : 2000 participants Observational Model: Cohort Time Perspective: Prospective Target Follow-Up (...) Intervention/treatment Early stage of MCI symptoms Subjects with cognitive decline representing MCI symptomology and with previous PET amyloid-beta (Aβ) imaging results. Device: EEG scan WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings Outcome Measures Go to Primary Outcome Measures

2018 Clinical Trials

146. Investigating the Efficacy of Caloric Vestibular Stimulation in the Treatment of Substance Use Disorders

in MRI and asked to fill out the same battery of questions. Consistent with the existing standard of care participants will also receive two urine drug screens (UDS) Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 24 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Intervention Model Description: This study is designed as a nonrandomized, single-blind, sham-controlled trail in which willing (...) malformations of or existing trauma to the external auditory canal Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03652311 Contacts Layout table for location contacts Contact: Margaret R Rukstalis, MD (336) 716-3426 Contact: Christopher Whitlow, Ph.D, MD

2018 Clinical Trials

147. Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia

symptoms despite stable outpatient treatment. Participants will undergo an initial screening session to complete informed consent and undergo baseline assessments of negative symptom severity. These assessments include reporter-based measures such as the Positive And Negative Syndrome Scale (PANSS) as well as quantitative tests of amotivation/anhedonia and diminished expressivity. Participants will then undergo an MRI scan that includes structural and resting state functional magnetic resonance imaging (...) with DLPFC targeted rTMS Secondary Outcome Measures : Change in Cerebellar - Prefrontal Functional Connectivity [ Time Frame: Before treatment (Baseline) and 1 week post treatment ] We will evaluate the effect of sham vs active rTMS on cerebellar-prefrontal cortex functional connectivity in the group with Cerebellar targeted rTMS and in the group with DLPFC targeted rTMS Change in Auditory Hallucination Severity [ Time Frame: Before treatment (Baseline) and 1 week post treatment ] We will evaluate

2018 Clinical Trials

148. Sound Processing Changes in Babies With Opioid Exposure

opioid exposure non-opioid exposed neonates no prenatal opioid exposure Outcome Measures Go to Primary Outcome Measures : Percent with neonates with auditory cortical processing deficiencies [ Time Frame: baseline ] A bone conducting sound playback lead will be placed over a bony prominence on the skull to transmit the auditory oddball paradigm that will be repeatedly played via this lead. The oddball paradigm will consist of a repeating sound loop including multiple identical 5-30 decibels tones (...) Investigators with routine access to infant and maternal records will identify subjects based on review of patient charts upon admission to the NICU or nursery. Criteria Inclusion Criteria: Gestational age ≥ 36 weeks, confirmation of dates via ultrasound or last menstrual period Prenatal opioid exposure ("exposed"), confirmed via admitted use or newborn drug screen; no prenatal opioid exposure ("control") by maternal report or testing All races, ethnicities, sexes to be included Informed permission form

2018 Clinical Trials

149. Metformin for Motor and Cognitive Improvement in Children With Cerebral Palsy: A Feasibility Study

, processing speed, episodic and working memory. Children's Auditory Verbal Learning Test-2 [CAVLT-2] [ Time Frame: Change in CAVLT-2 measures from baseline to 40 weeks ] The Children's Auditory Verbal Learning Test-2 [CAVLT-2] provides measures of immediate memory span as well as immediate and delayed recall. This will allow assessment of the extent of deficits within the areas of auditory verbal learning and memory. CAVLT-2 is applicable for children aged 6.6 to 17.11 years of age (...) hospitalization No lower extremity orthopedic surgery in the last year No acute or chronic metabolic acidosis and/or lactic acidosis over the lifespan, including a lactate level greater than 2 mmol/L at the screening visit. No history of renal disease Age 5 to 12 years, 11 months at the time of enrollment Either declare English as their native language or have had at least two years of schooling in English at the time of their baseline assessment Gross Motor Function Classification System Level of II - V

2018 Clinical Trials

150. Immersive Virtual Reality to Reduce Procedural Pain During IV Insertion in Children in the Emergency Department

in the pediatric emergency department. The study will consist of two study arms, where both study arms will be screened and recruited using the same procedure. Participants will be randomized into either (1) Control group: child life specialist plays an age-appropriate video on a tablet device, or (2) Intervention (VR Distraction): child life specialist facilitates immersive VR experience. Both the intervention and control groups will receive standard medical care (e.g., topical anesthetics). A convenience (...) Identifier: NCT03435367 Recruitment Status : Recruiting First Posted : February 16, 2018 Last Update Posted : July 20, 2018 See Sponsor: The Hospital for Sick Children Information provided by (Responsible Party): Jennifer Stinson, The Hospital for Sick Children Study Details Study Description Go to Brief Summary: Venipuncture and intravenous (IV) access continue to be the most common causes of pain and distress among children in the pediatric emergency department. Virtual reality has been successful

2018 Clinical Trials

151. Music Role in PD Rehabilitation

: Neurologic Music Therapy (NMT) sensorimotor techniques are increasingly used to improve spatio-temporal gait parameters and postural stability in the course of Parkinson's Disease and following stroke. Nonetheless, the neurophysiological underpinnings of NMT-mediated gait recovery is still poorly understood. The aim of the study was to investigate the central mechanisms of connectivity related to the application of Rhythmic Auditory Stimulation (RAS) in PD gait rehabilitation. The investigators (...) Phase Parkinson Disease Device: Gait Trainer 3 Not Applicable Detailed Description: The aim of the study was to investigate the central mechanisms of connectivity related to the application of Rhythmic Auditory Stimulation (RAS) in PD gait rehabilitation. The investigators will enroll 30 patients with PD. They will be randomized into two groups: (A) gait training with Music; (B) conventional treadmill gait training. The experimental group will perform training by means of GT3 (Biodex), where

2018 Clinical Trials

152. Arbaclofen in Children and Adolescents With ASD

of electrophysiology (EEG) are associated with either response to treatment [ Time Frame: Week 0 + Week 16 ] Induced power at 10Hz & 40Hz is assessed with an Auditory Steady State Response task. Explore whether induced and evoked power at 6Hz & 10Hz as measures of electrophysiology (EEG) are associated with either response to treatment [ Time Frame: Week 0 + Week 16 ] Induced and evoked power at 6Hz & 10Hz are assessed with a Visual Steady State Response task. Explore whether P1, N1 amplitude and latency (...) for a Module 3 or 4. Current pharmacological treatment regimen affecting behaviour has been stable for at least 6 weeks prior to screening and is expected to be stable during the duration of the study Current psychotherapeutic/psychosocial interventions affecting behaviour stable for 3 months prior to screening and expected to be stable during the duration of the study (standard regular school breaks and/or annual teacher/classroom change do not qualify for intervention change). Subjects with a history

2018 Clinical Trials

153. Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®): Health Professional Version

and/or systemic immunity Mucosal breakdown Salivary gland dysfunction Acquired pathogens Taste dysfunction Taste receptor toxicity Xerostomia Salivary gland toxicity Anticholinergic drugs Neuropathies Vinca alkaloid, thalidomide, bortezomib drug use; risk for specific drug toxicity varies Anemia, dental hypersensitivity, temporomandibular dysfunction/myofascial pain Dental and skeletal growth and development (pediatric patients) Specific drug toxicity Stage of dental and skeletal maturation Gastrointestinal (...) , bacterial). Chronic GVHD. Dental/skeletal growth and development alterations (pediatric patients). Xerostomia. Relapse-related oral lesions. Second malignancies. Phase V: Long-term Survival Relapse or second malignancies. Dental/skeletal growth and development alterations. GVHD = graft-versus-host disease. Phase I: Before Chemotherapy Oral complications are related to current systemic and oral health, oral manifestations of underlying disease, and oral complications of recent cancer or other medical

2016 PDQ - NCI's Comprehensive Cancer Database

154. Langerhans Cell Histiocytosis Treatment (PDQ®): Health Professional Version

[Internet]. Bethesda (MD): ; 2002-. Search term Langerhans Cell Histiocytosis Treatment (PDQ®) Health Professional Version PDQ Pediatric Treatment Editorial Board . Published online: November 13, 2018. Created: April 14, 2009 . This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood and adult Langerhans cell histiocytosis. It is intended as a resource to inform and assist clinicians who care (...) for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). General Information About Langerhans Cell Histiocytosis (LCH

2016 PDQ - NCI's Comprehensive Cancer Database

155. Langerhans Cell Histiocytosis Treatment (PDQ®): Health Professional Version

[Internet]. Bethesda (MD): ; 2002-. Search term Langerhans Cell Histiocytosis Treatment (PDQ®) Health Professional Version PDQ Pediatric Treatment Editorial Board . Published online: November 13, 2018. Created: April 14, 2009 . This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood and adult Langerhans cell histiocytosis. It is intended as a resource to inform and assist clinicians who care (...) for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). General Information About Langerhans Cell Histiocytosis (LCH

2016 PDQ - NCI's Comprehensive Cancer Database

156. Late Effects of Treatment for Childhood Cancer (PDQ®): Health Professional Version

–specific toxicity has motivated investigations evaluating the pathophysiology and prognostic factors for cancer treatment–related effects. The results of these studies have played an important role in the following areas:[ , ] Changing pediatric cancer therapeutic approaches to reduce treatment-related mortality among survivors treated in more recent eras. The development of risk counseling and health screening recommendations for long-term survivors by identifying the clinical and treatment (...) to Support Survivor Care Risk-based screening The need for long-term follow-up for childhood cancer survivors is supported by the American Society of Pediatric Hematology/Oncology, the International Society of Pediatric Oncology, the American Academy of Pediatrics, the Children’s Oncology Group (COG), and the Institute of Medicine. A risk-based medical follow-up is recommended, which includes a systematic plan for lifelong screening, surveillance, and prevention that incorporates risk estimates based

2016 PDQ - NCI's Comprehensive Cancer Database

157. Genetics of Kidney Cancer (Renal Cell Cancer) (PDQ®): Health Professional Version

, with the exception of HPRC, is associated with other benign or malignant tumors in other organs. Clinical Management Regular surveillance is a mainstay in individuals found to have or be at risk of carrying a pathogenic variant in VHL , FH , FLCN , or MET . Surveillance recommendations include regular screening for both renal and nonrenal manifestations of disease. of 3 cm in size are commonly managed with . Nephron-sparing techniques are typically employed as they have been shown to preserve renal function (...) on genetic screening for hereditary renal cell cancers. Can Urol Assoc J 7 (9-10): 319-23, 2013 Sep-Oct. [ ] [ ] McLaughlin JK, Lipworth L: Epidemiologic aspects of renal cell cancer. Semin Oncol 27 (2): 115-23, 2000. [ ] Brauch H, Weirich G, Hornauer MA, et al.: Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst 91 (10): 854-61, 1999. [ ] Chow WH, Devesa SS: Contemporary epidemiology of renal cell cancer. Cancer J 14 (5): 288-301, 2008 Sep

2016 PDQ - NCI's Comprehensive Cancer Database

158. Clinical Guidelines and Integrated Care Pathways for the Oral Health Care of People with Learning Disabilities

, self-esteem, self confidence and social acceptability as well as to good general health. Evidence confirms that people with learning disabilities have a lower uptake of screening services (Howells, 1986, Whitfield et al., 1996, Band, 1998) and poorer oral health when compared to the general population. A number of reports have examined the needs of people with learning disabilities. These guidelines focus on oral health care and how it can be improved through an approach which is focused (...) with a learning disability have a right to equal standards of health and care as the general population. However, there is evidence that they experience poorer general and oral health, have unmet health needs and have a lower uptake of screening services (Howells, 1986, Whitfield et al., 1996, Band, 1998). The impact of oral conditions on an individual’s quality of life can be profound (Locker, 1992). Poor oral health may add an additional burden whereas good oral health has holistic benefits in that it can

2012 Royal College of Surgeons of England

159. Last Days of Life (PDQ®): Health Professional Version

, although benzodiazepines (such as lorazepam) or atypical antipsychotics typically exacerbate delirium, they may be useful in delirium related to alcohol withdrawal and for hyperactive delirium that is not controlled by antipsychotics and other supportive measures. In intractable cases of delirium, palliative sedation may be warranted. In dying patients, a poorly understood phenomenon that appears to be distinct from delirium is the experience of auditory and/or visual hallucinations that include loved

2016 PDQ - NCI's Comprehensive Cancer Database

160. Composite Resin and Amalgam Dental Filling Materials: A Review of Safety, Clinical Effectiveness and Cost-effectiveness

, renal pathologies, or immunoreactions RCT=randomized controlled trial ; SAE=severe adverse events; TEAE=treatment emergent adverse events; Composite Resin and Amalgam Dental Filling 17 Appendix 2: Title and abstract screening checklist Reviewer: Date: Ref ID: First Author (year): 1 What is the STUDY POPULATION in this article? Pediatric patients/ deciduous teeth to be restored (exclude) Pediatric patients/ mixed dentition to be restored (include) Pediatric patients/ permanent teeth to be restored (...) assessments, systematic reviews, meta-analyses, randomized controlled trials, and economic studies. Where possible, retrieval was limited to the human population. The electronic search was also limited to English language documents published between January 1, 2002 and April 30, 2012. The bibliographies of the retrieved health technology assessments, systematic reviews, and meta-analyses were searched manually for relevant clinical trials. Selection Criteria and Methods One reviewer screened citations

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>